Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30703365 | 0.89 | JMJD6 (0.48) | JMJD6TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2629432 | 0.82 | TSHR (0.51) | JMJD6TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4939658 | 0.81 | — | — | |
| SCHEMBL27326239 | 0.80 | SMN1; SMN2 (0.50) | JMJD6TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29099643 | 0.80 | KMT2A (0.47) | JMJD6TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10154470 | 0.79 | JMJD6 (0.56) | JMJD6TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10817921 | 0.79 | TSHR (0.60) | JMJD6TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL27610277 | 0.79 | TSHR (0.49) | JMJD6TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL263713 | 0.78 | — | — | |
| SCHEMBL2629340 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119125413-A | Method for rapidly identifying grass carp variety and muscle characteristic flavor substances based on GC×GC-TOFMS technology | 湖南师范大学 | 2024-12-13 | — | — | CN | claimed |
| US-12433895-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12358919-B2 | Antibacterial compounds | UNIVERSITA' DEGLI STUDI DI SIENA (IT) | 2025-07-15 | — | — | US | disclosed |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | Mirati Therapeutics, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20250074920-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2025043191-A1 | PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE | ORIC PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| CN-101528687-A | Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same | KOREA RES INST CHEM TECH (KR) | 2009-09-09 | — | — | CN | disclosed |
| US-7501420-B2 | Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| CN-1925878-A | Contrast agents for myocardial perfusion imaging | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-03-07 | — | — | CN | disclosed |
| EP-0154132-B1 | 6-ALKYLIDENE PENEMS, THEIR PREPARATION AND USE, AND INTERMEDIATES | BEECHAM GROUP PLC (GB) | 1992-01-08 | — | — | EP | disclosed |
| US-4798828-A | LACTAMASE INHIBITORS | BEECHAM GROUP P.L.C. (GB) | 1989-01-17 | — | — | US | disclosed |
| EP-0154132-A1 | 6-Alkylidene penems, their preparation and use, and intermediates | BEECHAM GROUP PLC (GB) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433895-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | JMJD6 2559/4885TSHR 3788/4885RAB9A 1818/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | JMJD6 2285/4885TSHR 4687/4885RAB9A 3036/4885 |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | JMJD6 90/4885TSHR 4145/4885RAB9A 1122/4885 |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | JMJD6 1283/4885TSHR 4730/4885RAB9A 3788/4885 |
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | JMJD6 1534/4885TSHR 2897/4885RAB9A 2246/4885 |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | BMI1, EZH2, SUZ12 | JMJD6 158/4885TSHR 4611/4885RAB9A 1841/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | JMJD6 106/4885TSHR 4715/4885RAB9A 2161/4885 |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | JMJD6 1488/4885TSHR 4796/4885RAB9A 3288/4885 |
| US-20250074920-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | MAP3K20, MAP3K8, PRKACA | JMJD6 1631/4885TSHR 1670/4885RAB9A 1548/4885 |
| US-12358919-B2 | Antibacterial compounds | ABCB11, CFTR, MRPL21 | JMJD6 4392/4885TSHR 4772/4885RAB9A 1406/4885 |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | BMI1, EZH2, SUZ12 | JMJD6 158/4885TSHR 4611/4885RAB9A 1841/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | JMJD6 142/4885TSHR 4567/4885RAB9A 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.